UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Preferred Stock	Common Stock	Treasury Stock	Paid-in Capital	Management Notes Receivable	Accumulated Deficit	Accumulated Other Comprehensive (Loss) Income
Equity, beginning balance at Dec. 31, 2018	$ 602,825	$ 0	$ 14	$ 0	$ 619,621	$ (1,619)	$ (16,035)	$ 844
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(21)					(21)
Stockholders' redemption	(2,000)				(2,000)
Stock-based incentive compensation	584				584
Net loss	(3,712)						(3,712)
Other comprehensive income (loss)	(505)							(505)
Equity, ending balance at Mar. 31, 2019	597,171	0	14	0	618,205	(1,640)	(19,747)	339
Equity, beginning balance at Dec. 31, 2018	602,825	0	14	0	619,621	(1,619)	(16,035)	844
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(60,109)
Other comprehensive income (loss)	(8,727)
Equity, ending balance at Sep. 30, 2019	921,682	0	18	(2,399)	1,008,090	0	(76,144)	(7,883)
Equity, beginning balance at Mar. 31, 2019	597,171	0	14	0	618,205	(1,640)	(19,747)	339
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(18)					(18)
Stockholders' redemption	0				(371)	371
Stock-based incentive compensation	569				569
Net loss	(13,603)						(13,603)
Other comprehensive income (loss)	27							27
Equity, ending balance at Jun. 30, 2019	584,146	0	14	0	618,403	(1,287)	(33,350)	366
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Interest on management notes receivable	(23)					(23)
Stock-based incentive compensation	2,745				2,745
Repayment of management notes receivable	1,310					1,310
Purchase of BioScrip, Inc.	387,044		4		387,040
Exercise of stock options, vesting of restricted stock and related tax withholdings	(2,497)			(2,399)	(98)
Net loss	(42,794)						(42,794)
Other comprehensive income (loss)	(8,249)							(8,249)
Equity, ending balance at Sep. 30, 2019	921,682	0	18	(2,399)	1,008,090	0	(76,144)	(7,883)
Equity, beginning balance at Dec. 31, 2019	906,827	0	18	(2,403)	1,008,362	0	(91,955)	(7,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based incentive compensation	757				757
Exercise of stock options, vesting of restricted stock and related tax withholdings	(549)				(549)
Net loss	(19,910)						(19,910)
Other comprehensive income (loss)	(16,632)							(16,632)
Equity, ending balance at Mar. 31, 2020	870,493	0	18	(2,403)	1,008,570	0	(111,865)	(23,827)
Equity, beginning balance at Dec. 31, 2019	906,827	0	18	(2,403)	1,008,362	0	(91,955)	(7,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(25,915)
Other comprehensive income (loss)	(8,034)
Equity, ending balance at Sep. 30, 2020	993,496	0	19	(2,403)	1,128,979	0	(117,870)	(15,229)
Equity, beginning balance at Mar. 31, 2020	870,493	0	18	(2,403)	1,008,570	0	(111,865)	(23,827)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based incentive compensation	661				661
Exercise of stock options, vesting of restricted stock and related tax withholdings	(96)				(96)
Net loss	(7,668)						(7,668)
Other comprehensive income (loss)	4,576							4,576
Equity, ending balance at Jun. 30, 2020	867,966	0	18	(2,403)	1,009,135	0	(119,533)	(19,251)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based incentive compensation	1,170				1,170
Exercise of stock options, vesting of restricted stock and related tax withholdings	(259)				(259)
Net proceeds from the issuance of common stock	118,934		1		118,933
Net loss	1,663						1,663
Other comprehensive income (loss)	4,022							4,022
Equity, ending balance at Sep. 30, 2020	$ 993,496	$ 0	$ 19	$ (2,403)	$ 1,128,979	$ 0	$ (117,870)	$ (15,229)